Open-Source Decision Model for Value Assessment Rheumatoid Arthritis Treatments

In a recently published paper in PharmacoEconomics, I–along with co-authors Devin Incerti, Jeff Curtis, Darius Lakdawalla, and Jeroen Jansen–describe a recently developed open-source platform for measuring the value of treatments for rheumatoid arthritis. The model itself is here, but and the abstract from Incerti et al. (2019) is below:

Objective

The nature of model-based cost-effectiveness analysis can lead to disputes in the scientific community. We propose an iterative and collaborative approach to model development by presenting a flexible open-source simulation model for rheumatoid arthritis (RA), accessible to both technical and non-technical end-users.

Methods

The RA model is a discrete-time individual patient simulation with 6-month cycles. Model input parameters were estimated based on currently available evidence and treatment effects were obtained with Bayesian network meta-analysis techniques. The model contains 384 possible model structures informed by previously published models. The model consists of the following components: (i) modifiable R and C++ source code available in a GitHub repository; (ii) an R package to run the model for custom analyses; (iii) detailed model documentation; (iv) a web-based user interface for full control over the model without the need to be well-versed in the programming languages; and (v) a general audience web-application allowing those who are not experts in modeling or health economics to interact with the model and contribute to value assessment discussions.

Results

A primary function of the initial version of RA model is to help understand and quantify the impact of parameter uncertainty (with probabilistic sensitivity analysis), structural uncertainty (with multiple competing model structures), the decision framework (cost-effectiveness analysis or multi-criteria decision analysis), and perspective (healthcare or limited societal) on estimates of value.

Conclusion

In order for a decision model to remain relevant over time it needs to evolve along with its supporting body of clinical evidence and scientific insight. Multiple clinical and methodological experts can modify or contribute to the RA model at any time due to its open-source nature.

Citation:

• Incerti, D., Curtis, J.R., Shafrin, J., Lakdawalla, D.N., Jansen, J.P. “A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis” PharmacoEconomics (2019). http://bit.ly/2SMjU4U

from Healthcare Economist http://bit.ly/2DsANIk